Real-world evidence on the efficacy, safety, and biomarkers of immunotherapy combined with radiotherapy in limited-stage small cell lung cancer - PubMed
7 hours ago
- #immunotherapy
- #radiotherapy
- #small cell lung cancer
- Study explores immunotherapy combined with radiotherapy in limited-stage small cell lung cancer (LS-SCLC).
- 32 patients treated with ICIs and chemotherapy, followed by radiotherapy, showed high response rates (ORR 93.7%, DCR 100%).
- Median PFS was 16.3 months and median OS was 37 months for first-line treatment.
- Key adverse events included grade 3/4 myelosuppression (15.6%) and radiation pneumonitis (18.7%).
- PLR (Platelet-to-Lymphocyte Ratio) >101.75 at baseline predicted longer PFS.
- LDH normalization during treatment suggested favorable response, though not statistically significant.
- Elevated NSE and ProGRP trends correlated with shorter PFS.
- The combination therapy is feasible, safe, and effective for LS-SCLC.